Visceral Leishmaniasis: Understanding, Treating, and Preventing This Tropical Disease
"Learn about visceral leishmaniasis (VL), a severe parasitic disease, including its causes, symptoms, treatments, and prevention strategies, and recent developments in research."
Visceral leishmaniasis (VL), also known as Kala-azar, is the most severe form of leishmaniasis, a parasitic disease transmitted through the bite of infected female sandflies. The disease primarily affects the internal organs, such as the spleen, liver, and bone marrow. If left untreated, VL is almost always fatal.
Visceral leishmaniasis is prevalent in certain tropical and subtropical regions, particularly in parts of Africa, Asia, and South America. According to the World Health Organization (WHO), an estimated 50,000 to 90,000 new cases occur globally each year. The disease disproportionately affects populations living in poverty, with limited access to healthcare and sanitation.
This article aims to provide a comprehensive overview of visceral leishmaniasis, covering its causes, symptoms, diagnosis, treatment, and prevention strategies. Understanding the complexities of VL is crucial for healthcare professionals, researchers, and individuals living in or traveling to affected regions.
A Persistent Burden Across Four Regions
According to PAHO/WHO, leishmaniasis continues to be a major health problem in four eco-epidemiological regions of the world: the Americas, East Africa, North Africa, and Western and Southeast Asia. Tracking the true scale of visceral leishmaniasis (VL) is complicated by the level at which surveillance data are collected, since data are more easily collated at larger administrative units while village-level patterns of incidence are harder to observe directly. Field studies add to the picture of hidden impact, with surveillance in western Ethiopia measuring asymptomatic visceral leishmaniasis at the kebele level using the leishmanin skin test between 2018 and 2020.
Diagnosis and Treatment Under Strain
Conventional diagnostic modalities for visceral leishmaniasis—including microscopy, in vitro culture, and serological assays—are constrained by suboptimal sensitivity, invasive sampling, and prolonged turnaround times. These serological approaches build on the disease's biology, since hyperimmunoglobulinaemia is a hallmark of visceral leishmaniasis and is exploited for diagnosis. Treatment carries its own limitations: in immunocompromised patients especially, VL often presents with an atypical and fulminant course, and management faces multiple challenges including drug toxicity, the patient's immunosuppressive status, and complications.
From Misdiagnosed Malaria to Modern Diagnostics
Kala-azar first came to the attention of Western doctors in 1824 in Jessore, British Raj (now Bangladesh), where it was initially thought to be a form of malaria. Foundational diagnostic progress came from direct visualization of the amastigotes (Leishman–Donovan bodies) in bone marrow aspirates in the hematology laboratory. Later milestones shifted toward serology: the Brazilian branch of one research team pushed for the adoption of an ELISA test based on the detection of antibodies in the blood—a method that saved a young patient's life and has since been adopted as standard in Paraná.
Causes and Transmission
Visceral leishmaniasis is caused by protozoan parasites belonging to the Leishmania genus. The parasites are transmitted to humans through the bite of infected female phlebotomine sandflies. These tiny insects are typically most active during dusk and dawn. Several species of Leishmania parasites can cause VL, with Leishmania donovani and Leishmania infantum being the most common.
- Living in or traveling to endemic regions.
- Poverty and poor living conditions.
- Malnutrition and weakened immune systems.
- Co-infection with HIV.
A Live, Evolving Evidence Base
Visceral leishmaniasis research is a live field, with science news outlets regularly publishing updates, advancements, and breakthroughs from laboratories and field sites. At the heart of this evidence base is a stark severity signal: the Infectious Diseases Data Observatory reports that VL is a neglected tropical disease that threatens tens of thousands of people each year, mostly in the world's poorest communities, and is fatal in over 95% of cases if left untreated. Recent surveillance in Brazil reinforces that the burden is not shrinking, with new cases continuing to be reported and spreading across municipalities in São Paulo State despite public policy planning.
Where Control Efforts Fall Short
Despite the existence of diagnostic and blood testing options, visceral leishmaniasis control has a record of setbacks. The disease is a parasitic infection affecting internal organs, and its treatment is very challenging, with few treatment options available. Long duration of treatment and drug toxicity further limit the goal of achieving VL elimination. These persistent failures help explain why, even in endemic regions with established protocols, visceral leishmaniasis remains hard to contain.
Comparing Forms, Diagnostics, and Outcomes
Leishmaniasis is a parasitic disease caused by protozoans of the genus Leishmania that are transmitted to humans by the bite of a female sand fly vector, and its clinical forms include cutaneous and visceral leishmaniasis. Visceral leishmaniasis is specifically a systemic protozoan disease transmitted by phlebotomine sandflies, with poor and neglected populations in East Africa and the Indian subcontinent particularly affected. Across these settings, early and accurate diagnosis and treatment remain key components of VL control. Comparative diagnostic research has also focused on outcomes, using anti-Leishmania IgG1 antibodies to monitor post-chemotherapeutic treatment outcome in VL and to help diagnose post kala-azar dermal leishmaniasis (PKDL).
The Future of VL Research
Despite the challenges posed by visceral leishmaniasis, ongoing research efforts offer hope for improved diagnostics, treatments, and prevention strategies. Scientists are exploring novel drug targets, developing more effective vaccines, and implementing innovative vector control methods. With continued investment and collaboration, the global community can make significant progress in reducing the burden of this neglected tropical disease and improving the lives of millions.
Expert Consensus: Neglect, Evidence, and Realism
Expert commentary consistently characterizes visceral leishmaniasis as one of the most neglected parasitic diseases, causing large-scale mortality and morbidity among the poorest of the poor in the Indian subcontinent and Africa. The clinical picture is well established: VL is caused by a parasite and results in fever, a large spleen, and other health problems, and it occurs in India, Bangladesh, Nepal, east Africa, the Mediterranean region, and Brazil. Within this landscape, experts have examined the evidence for existing therapies, including a retrospective analysis of nearly 5,000 VL patients in East Africa treated primarily with pentavalent antimonials that demonstrated their continued efficacy, with relatively low rates of relapse or death.
Investment Meets Therapeutic Constraints
The commercial outlook for visceral leishmaniasis is expanding, with one industry report projecting the market to reach USD 1.72 billion at a 4.95% compound annual growth rate over the 2025–2035 forecast period. The clinical stakes behind that growth are severe, since VL is a potentially lethal systemic disease characterized by darkening of the skin as well as the pentad of fever, weight loss, hepatosplenomegaly, pancytopenia, and hypergammaglobulinemia. Yet the therapeutic frontier remains constrained: treatment of VL is very challenging, with few options, and long durations of treatment and drug toxicity continue to limit the goal of achieving elimination.
Environment, Housing, and Neglect
Visceral leishmaniasis is embedded in a broader landscape of neglected tropical diseases shaped by environment and poverty. If untreated, visceral leishmaniasis can be fatal. Leishmaniasis predominantly affects tropical and subtropical regions, where warm, humid conditions and poor housing favor the survival of sandflies, linking transmission risk to both climate and living conditions.
Poverty, Place, and the People Affected
Visceral leishmaniasis is an insidious neglected disease with worldwide distribution, caused by parasites from the Leishmania donovani complex that can be transmitted by different species of phlebotomine sand flies and can infect numerous mammal hosts. The disease's distribution is heavily influenced by environmental conditions, including weather extremes, and this neglected tropical zoonosis has shown increasing urbanization since the end of the 1980s. The human cost falls hardest on the poor: cases of visceral leishmaniasis, and especially those that end in death, tend to occur in rural, impoverished areas, often because there is little to no access to treatment or a lack of funds to afford it.